In a surprising move, the Trump administration has invested $500 million in a vaccine technology that many scientists are calling outdated. The investment, which was announced last week, has left many experts scratching their heads and wondering why the administration would choose to bet such a large sum of money on a technology that is considered by many to be less effective than newer, more advanced options.

The technology in question is known as recombinant DNA technology, which has been around for decades and is used in some existing vaccines. However, many scientists argue that newer technologies, such as mRNA vaccines, have proven to be more effective and have a higher success rate in preventing infectious diseases.

The Trump administration’s decision to invest in this older technology has raised concerns among public health officials and experts, who worry that the investment may not yield the desired results in the fight against COVID-19 and other infectious diseases. Some critics have even gone so far as to suggest that the investment may be politically motivated, rather than based on sound scientific evidence.

Despite the skepticism surrounding the decision, the Trump administration remains confident in its choice and has defended the investment as a necessary step in the fight against the ongoing pandemic. Only time will tell whether this $500 million bet on old vaccine technology will pay off in the end.

Compra prodotti su Amazon

Source: KFF Health News